Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study

Clin Infect Dis. 2007 Jul 15;45(2):263-6. doi: 10.1086/518973. Epub 2007 Jun 6.

Abstract

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.

Publication types

  • Clinical Trial, Phase IV
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Benzoxazines / administration & dosage
  • Benzoxazines / adverse effects
  • Cholesterol, LDL / blood*
  • Cholesterol, LDL / drug effects
  • Coronary Disease / chemically induced
  • Coronary Disease / prevention & control
  • Cross-Over Studies
  • Cyclopropanes
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Dyslipidemias / blood
  • Dyslipidemias / chemically induced
  • Dyslipidemias / prevention & control*
  • Female
  • Follow-Up Studies
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Nevirapine / administration & dosage*
  • Nevirapine / adverse effects
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Reverse Transcriptase Inhibitors / adverse effects
  • Severity of Illness Index
  • Single-Blind Method
  • Treatment Outcome

Substances

  • Alkynes
  • Benzoxazines
  • Cholesterol, LDL
  • Cyclopropanes
  • Reverse Transcriptase Inhibitors
  • Nevirapine
  • efavirenz